Insider Selling: Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells $573,110.72 in Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 157,448 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $3.64, for a total transaction of $573,110.72. Following the completion of the transaction, the chief executive officer now directly owns 3,143,753 shares of the company’s stock, valued at approximately $11,443,260.92. The trade was a 4.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Organogenesis Stock Down 3.7 %

ORGO stock opened at $3.40 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The stock has a market capitalization of $450.77 million, a P/E ratio of -56.67 and a beta of 1.73. Organogenesis Holdings Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $4.70. The business has a 50-day moving average of $3.43 and a 200-day moving average of $2.99.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. During the same quarter in the prior year, the firm posted $0.02 EPS. On average, sell-side analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ORGO. Assenagon Asset Management S.A. boosted its stake in shares of Organogenesis by 309.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock worth $11,136,000 after buying an additional 3,005,450 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Organogenesis by 2.4% in the second quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after acquiring an additional 72,696 shares during the last quarter. AQR Capital Management LLC raised its holdings in Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after acquiring an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Organogenesis by 19.6% in the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after purchasing an additional 333,123 shares in the last quarter. Finally, State Street Corp increased its position in shares of Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after purchasing an additional 9,090 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.